MedTrace Logo

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-08-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and tolerability of an investigational meningococcal B rLP2086 vaccine in healthy adults.

Conditions

  • Meningitis, Meningococcal

Interventions

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00879814 on ClinicalTrials.gov